Company Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.
Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS.
It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V.
and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
| Country | Germany |
| Founded | 2007 |
| IPO Date | Nov 8, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Niels Riedemann |
Contact Details
Address: Winzerlaer Str. 2 Jena, 07745 Germany | |
| Phone | 49 3641 508 180 |
| Website | inflarx.de |
Stock Details
| Ticker Symbol | IFRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001708688 |
| CUSIP Number | N44821101 |
| ISIN Number | NL0012661870 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Niels C. Riedemann M.D., Ph.D. | Co-Founder, Chief Executive Officer and Executive Director |
| Prof. Renfeng Guo M.D. | Co-Founder, Chief Scientific Officer and Executive Director |
| Dr. Thomas Taapken Ph.D. | Chief Financial Officer |
| Derval O'Carroll | Senior Vice President and Global Head of Regulatory Affairs and Compliance |
| Dr. Camilla Chong M.D. | Chief Medical Officer |
| Jan Medina CFA | Head of Investor Relations and Vice President |
| Christian Schmid | Vice President and Head of Legal Affairs and General Counsel |
| Nicole Bertsch | Senior Director and Head of Human Resources |
| Dr. Maria Habel PH.D. | Vice President, Head of Preclinical Research & Development and QC |
| Dr. Bruce P. Burnett Ph.D. | Vice President and Head of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 424B5 | Filing |
| Feb 13, 2025 | 424B5 | Filing |
| Jan 15, 2025 | 6-K | Report of foreign issuer |
| Dec 20, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |
| Aug 8, 2024 | 6-K | Report of foreign issuer |